April 23, 2024

NOTIFICATION PURSUANT TO

18 V.S.A. § 4637(b)

Subject: New prescription drug report

To: The Office of the Attorney General of Vermont;
Via E-Mail: AGO.highcostprescriptiondrugs@vermont.gov

Ingenus Pharmaceuticals, LLC hereby submits to the Attorney General of Vermont the following new prescription drug reporting requirements pursuant to 18 V.S.A. § 4637(b):

Name of New Prescription Drug	NDC Number	Date of Commercial Availability	Wholesale Acquisition Cost as of the date of Commercial Availability
DOCIVYX 20mg/2mL	83831010102	4/23/2024	$990.00
DOCIVYX 80mg/8mL	83831010208	4/23/2024	$3960.00
DOCIVYX 160mg/16mL	83831010316	4/23/2024	$7920.00

Marketing Plan Description:

DOCIVYX will be launched in the U.S. for appropriate and eligible patients treated at oncology clinics and hospitals. All marketing, sales, and promotional activities messages will be limited to the approved product label data and information.

Estimated Number of Patients:

Avyxa Pharma, LLC does not track the number of patients.

Breakthrough Therapy/Priority Review/Acquisition Date:

The FDA did not grant DOCIVYX breakthrough therapy designation or priority review. The product was acquired on 7/3/2023, but the previous owner did not market or sell the product.

Avyxa Pharma, LLC believes that this report contains all the required report elements for a new prescription drug report. Please let us know if any additional information is required.

Sincerely,

Sandy Fischer
Associate VP, Compliance & Commercial Operations
Ingenus Pharmaceuticals, LLC